Cadrenal Therapeutics, Inc. 8-K

What Happened

• Cadrenal Therapeutics, Inc. filed a Current Report on Form 8-K on March 31, 2026 (Item 2.02) to announce financial information for the fiscal year ended December 31, 2025.
• The company issued a press release with those results; the press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: March 31, 2026.
• Reporting period: fiscal year ended December 31, 2025.
• The press release containing the financial information is attached to the 8-K as Exhibit 99.1.
• The Form 8-K also includes the interactive XBRL cover page (Exhibit 104).

Why It Matters

• This filing formally notifies investors that Cadrenal has released its full-year 2025 operating and financial results — key information for assessing revenue, profitability, cash position and outlook.
• Retail investors should read the attached press release (Exhibit 99.1) and any subsequent SEC filings (e.g., 10‑K) for the detailed numbers, management commentary, and any disclosure about liquidity, guidance, or material events that could affect the stock.